175 related articles for article (PubMed ID: 35070257)
21. Lee Silverman voice treatment (LSVT) mitigates voice difficulties in mild Parkinson's disease.
Saffarian A; Amiri Shavaki Y; Shahidi GA; Hadavi S; Jafari Z
Med J Islam Repub Iran; 2019; 33():5. PubMed ID: 31086784
[No Abstract] [Full Text] [Related]
22. Multidimensional voice assessment after Lee Silverman Voice Therapy (LSVT
Marchese MR; Proietti I; Longobardi Y; Mari G; Ausili Cefaro C; D'Alatri L
Acta Otorhinolaryngol Ital; 2022 Aug; 42(4):348-354. PubMed ID: 36254651
[TBL] [Abstract][Full Text] [Related]
23. Intensive voice treatment (the Lee Silverman Voice Treatment [LSVT
Ertan E; Gürvit HI; Hanağası HH; Bilgiç B; Tunçer MA; Yılmaz C
Logoped Phoniatr Vocol; 2022 Dec; 47(4):262-270. PubMed ID: 34287100
[No Abstract] [Full Text] [Related]
24. Single Word Intelligibility of Individuals with Parkinson's Disease in Noise: Pre-Specified Secondary Outcome Variables from a Randomized Control Trial (RCT) Comparing Two Intensive Speech Treatments (LSVT LOUD vs. LSVT ARTIC).
Schulz G; Halpern A; Spielman J; Ramig L; Panzer I; Sharpley A; Freeman K
Brain Sci; 2021 Jun; 11(7):. PubMed ID: 34199093
[TBL] [Abstract][Full Text] [Related]
25. Effects of an intensive voice treatment on articulatory function and speech intelligibility in children with motor speech disorders: A phase one study.
Langlois C; Tucker BV; Sawatzky AN; Reed A; Boliek CA
J Commun Disord; 2020; 86():106003. PubMed ID: 32505858
[TBL] [Abstract][Full Text] [Related]
26. Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: a pilot randomised controlled trial (PD COMM pilot).
Sackley CM; Smith CH; Rick CE; Brady MC; Ives N; Patel S; Woolley R; Dowling F; Patel R; Roberts H; Jowett S; Wheatley K; Kelly D; Sands G; Clarke CE;
Pilot Feasibility Stud; 2018; 4():30. PubMed ID: 29344405
[TBL] [Abstract][Full Text] [Related]
27. Effects of Intensive Voice Treatment (The Lee Silverman Voice Treatment [LSVT LOUD]) in Subjects With Multiple Sclerosis: A Pilot Study.
Baldanzi C; Crispiatico V; Foresti S; Groppo E; Rovaris M; Cattaneo D; Vitali C
J Voice; 2022 Jul; 36(4):585.e1-585.e13. PubMed ID: 32819780
[TBL] [Abstract][Full Text] [Related]
28. Respiratory Responses to Two Voice Interventions for Parkinson's Disease.
Richardson K; Huber JE; Kiefer B; Kane C; Snyder S
J Speech Lang Hear Res; 2022 Oct; 65(10):3730-3748. PubMed ID: 36167066
[TBL] [Abstract][Full Text] [Related]
29. Effect of Lee Silverman Voice Treatment (LSVT)® BIG on motor symptoms in a patient with severe Parkinson's disease: a case report.
Hirakawa Y; Takeda K; Koyama S; Naoi Y; Matsushita T; Nagai T; Motoya I; Sakurai H; Kanada Y; Kawamura N; Kawamura M; Tanabe S
Physiother Theory Pract; 2022 Nov; 38(13):3159-3168. PubMed ID: 34125001
[TBL] [Abstract][Full Text] [Related]
30. The Lee Silverman Voice Treatment (LSVT®) speech therapy in progressive supranuclear palsy.
Sale P; Castiglioni D; De Pandis MF; Torti M; Dall'armi V; Radicati FG; Stocchi F
Eur J Phys Rehabil Med; 2015 Oct; 51(5):569-74. PubMed ID: 26138088
[TBL] [Abstract][Full Text] [Related]
31. Hypokinetic Dysarthria in Parkinson's Disease: A Narrative Review.
Atalar MS; Oguz O; Genc G
Sisli Etfal Hastan Tip Bul; 2023; 57(2):163-170. PubMed ID: 37899809
[TBL] [Abstract][Full Text] [Related]
32. Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson's disease: a comparison with untreated patients and normal age-matched controls.
Ramig LO; Sapir S; Fox C; Countryman S
Mov Disord; 2001 Jan; 16(1):79-83. PubMed ID: 11215597
[TBL] [Abstract][Full Text] [Related]
33. Innovative technology for the assisted delivery of intensive voice treatment (LSVT®LOUD) for Parkinson disease.
Halpern AE; Ramig LO; Matos CE; Petska-Cable JA; Spielman JL; Pogoda JM; Gilley PM; Sapir S; Bennett JK; McFarland DH
Am J Speech Lang Pathol; 2012 Nov; 21(4):354-67. PubMed ID: 23071195
[TBL] [Abstract][Full Text] [Related]
34. Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance-correlation analysis.
Narayana S; Fox PT; Zhang W; Franklin C; Robin DA; Vogel D; Ramig LO
Hum Brain Mapp; 2010 Feb; 31(2):222-36. PubMed ID: 19639554
[TBL] [Abstract][Full Text] [Related]
35. Neural Correlates of Hypokinetic Dysarthria and Mechanisms of Effective Voice Treatment in Parkinson Disease.
Baumann A; Nebel A; Granert O; Giehl K; Wolff S; Schmidt W; Baasch C; Schmidt G; Witt K; Deuschl G; Hartwigsen G; Zeuner KE; van Eimeren T
Neurorehabil Neural Repair; 2018 Dec; 32(12):1055-1066. PubMed ID: 30444176
[TBL] [Abstract][Full Text] [Related]
36. Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial.
Scobie S; Jowett S; Lambe T; Patel S; Woolley R; Ives N; Rick C; Smith C; Brady MC; Clarke C; Sackley C
Pilot Feasibility Stud; 2021 Aug; 7(1):154. PubMed ID: 34372913
[TBL] [Abstract][Full Text] [Related]
37. Feasibility and Acceptability of Lee Silverman Voice Treatment in Progressive Ataxias.
Lowit A; Egan A; Hadjivassiliou M
Cerebellum; 2020 Oct; 19(5):701-714. PubMed ID: 32588316
[TBL] [Abstract][Full Text] [Related]
38. Delivering the Lee Silverman Voice Treatment (LSVT) by web camera: a feasibility study.
Howell S; Tripoliti E; Pring T
Int J Lang Commun Disord; 2009; 44(3):287-300. PubMed ID: 18821113
[TBL] [Abstract][Full Text] [Related]
39. The impact of PD Check-In on self-management skills for maintenance of speech after intensive treatment.
Finnimore A; Theodoros D; Rumbach AF
Int J Lang Commun Disord; 2024 Feb; ():. PubMed ID: 38377119
[TBL] [Abstract][Full Text] [Related]
40. Effects of Lee Silverman Voice Treatment (LSVT LOUD) on Swallowing in Patients with Progressive Supranuclear Palsy: A Pilot Study.
Nozaki S; Fujiu-Kurachi M; Tanimura T; Ishizuka K; Miyata E; Sugishita S; Imai T; Nishiguchi M; Furuta M; Yorifuji S
Prog Rehabil Med; 2021; 6():20210012. PubMed ID: 33644483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
